摘要
目的观察西黄胶囊联合复方苦参注射液辅助治疗结肠癌的临床疗效及安全性。方法将52例结肠癌术后患者随机分为对照组26例及试验组26例。对照组予以复方苦参注射液2 mL,qd,静脉滴注;试验组在对照组治疗的基础上,予以西黄胶囊每次2.0 g,bid,口服。2组患者均治疗56 d。比较2组患者的临床疗效、CD_3^+、CD_4^+、CD_8^+T淋巴细胞水平、CD_4^+/CD_8^+比值,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为53.85%(14/26例)和26.92%(7/26例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的CD_3^+分别为(66.08±8.11)%和(54.36±6.94)%,CD_4^+分别为(46.16±5.32)%和(25.46±3.16)%,CD_8^+分别为(23.26±3.14)%和(30.57±4.28)%,CD_4^+/CD_8^+分别为(1.98±0.26)和(0.83±0.11),差异均有统计学意义(均P<0.05)。2组患者的药物不良反应主要有白细胞减少、恶心呕吐、肝肾功能异常、血小板减少,且试验组和对照组的药物不良反应发生率分别为46.16%和76.92%,差异有统计学意义(P<0.05)。结论西黄胶囊联合复方苦参注射液辅助治疗结肠癌的临床疗效显著,其能够明显减轻患者免疫功能的损伤,减少化疗相关的药物不良反应。
Objective To observe the clinical efficacy and safety of Xi- huang capsules combined with compound matrine injection in the adju- vant treatment of colon cancer. Methods Fifty - two patients after colon cancer surgery were randomly divided into control group and treatment group with 26 cases per group. Control group was given compound ma- trine injection 2 mL, qd, intravenous drip. Treatment group was given Xihuang capsules 2. 0 g, bid, oral, on the basis of the control group. Two groups were treated for 56 d. The clinical efficacy, the levels of CD3, CD4+, CDs T lymphocytes, CD4+/CDs+ ratio and adverse drug reactions were compared between two groups. Results After treatment, the total effective rates in the treatment and control groups were 53.85% ( 14/26 cases) and 26. 92% ( 7/26 cases) with significant difference (P 〈 0. 05 ). After treatment, the main indexes in treatment and control groups were compared: CD3 ± were ( 66. 08 ± 8. 11 ) %, ( 54. 36 ± 6. 94) % ; CD4+ were (46.16± 5. 32)%, (25.46 ± 3. 16)%; CD8+ were (23.26 ±3.14)%, (30. 57 ±4. 28)% ; CD4+/CD8+ were (1.98 ±0.26),(0. 83 + 0. 11 ), the differences were statistically significant ( all P 〈 0.05 ). The adverse drug reactions in two groups were based on leukopenia, nausea and vomiting, liver and kidney dysfunction and thrombocytopenia. The incidences of adverse drug reactions in treatment and control groups were 46. 15% and 76. 92% with significant difference (P 〈0.05). Conclusion The combination of Xihuang capsules and compound matrine injection has a definitive clinical efficacy in the adjuvant treatment of colon cancer, which can significantly reduce the damage of the immune function of patients and chemotherapy - related adverse drug reactions.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2017年第16期1543-1545,共3页
The Chinese Journal of Clinical Pharmacology
基金
河南省医学科技攻关计划基金资助项目(201203047)
关键词
西黄胶囊
复方苦参注射液
结肠癌
安全性
Xihuang capsule
compound matrine injection
colon cancer
safety